Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of BI 1584862 in Healthy Males
NCT06006598Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1584862 in geographic atrophy (GA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related up to 27 days. Started Aug 2023; status: completed.
02
Drugs
BI 1584862
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06006598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006598.